Abstract:Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant tricuspid regurgitation. The development of new minimally invasive solutions potentially more adapted to this largely undertreated population of patients, has fuelled the interest for the tricuspid valve. Growing evidence and new concepts have contributed to revise obsolete and misleading perceptions around the right side of the heart. New definitions, classifications, and a better understanding of the disease pathophysiology and phenotypes, as well as their associated patient journeys have profoundly and durably changed the landscape of tricuspid disease. A number of registries and a recent randomized controlled pivotal trial provide preliminary guidance for decision-making. TTVI seem to be very safe and effective in selected patients, although clinical benefits beyond improved quality of life remain to be demonstrated. Even if more efforts are needed, increased disease awareness is gaining momentum in the community and supports the establishment of dedicated expert valve centres. This review is summarizing the achievements in the field and provides perspectives for a less invasive management of a no-more-forgotten disease. Disease stage and therapeutic strategies for tricuspid regurgitation. Tricuspid regurgitation evolves from undetectable early forms to advanced stages characterized by escalating symptoms, right heart failure, and organ impairment. While medical therapy is utilized throughout the disease course, its effectiveness wanes with progression. Surgery can play a role in the earlier stages, while transcatheter therapies are available for patients at high risk and in the more advanced stages of disease. Significant overlap between treatment options underscores the urgent need for precise, evidence-based protocols. Overall, early intervention is crucial to prevent organ damage and avoid futility of late treatments (smileys becoming sad). CAVI, caval valve implantation; RHF, right heart failure; TR, tricuspid regurgitation; RA, right atrial; RV, right ventricular; TTV, transcatheter tricuspid valve.

Patient selection for trans-catheter mitral valve repair versus replacement: ongoing indications and glimpse to the future

Update of Transcatheter Valve Treatment

Emerging Transcatheter Therapies for Valvular Heart Disease: Focus on Mitral and Tricuspid Valve Procedures

Device and Patient Selection

A deep dive into the percutaneous mitral valve data

Transcatheter treatment of the tricuspid valve: current status and perspectives

Transcatheter tricuspid valve interventions: Current status and future perspectives

Current Status of Catheter-based Mitral Valve Replacement

Multimodality imaging for preprocedural planning of percutaneous mitral valve repair: a comprehensive review

Transcatheter Interventions for Mitral Regurgitation: Multimodality Imaging for Patient Selection and Procedural Guidance

Ischemic functional mitral regurgitation: from pathophysiological concepts to current treatment options. A systemic review for optimal strategy

Current issues in transcatheter aortic valve replacement

The best way to transcatheter aortic valve implantation: From standard to new approaches

Transcatheter aortic valve implantation (TAVI): state of the art techniques and future perspectives

In silico approaches for transcatheter aortic valve replacement inspection

Rheumatic and Degenerative Mitral Stenosis: From an Iconic Clinical Case to the Literature Review

Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair

From Pre-Procedural Planning to Procedural Scenarios and Possible Complications

Transcatheter Treatment of Mitral Regurgitation: Current Status and Future Prospects

Transcatheter Tricuspid and Pulmonary Valve Repair and Replacement

Left ventricular assist device and transcatheter edge-to-edge mitral valve repair in advanced heart failure: allies or enemies?